Baptist Health partners with ALA in ‘Saved By the Scan’ campaign

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Baptist Health South Florida and the American Lung Association have partnered to raise awareness for lung cancer screenings through “Saved by the Scan,” a public service advertising campaign aimed at educating Americans about the low-dose CT scan available to those at high risk for the disease.

The low-dose CT scan can detect lung cancer in its early stages, before symptoms arise, when the disease is more curable.

In 2014, Mark Dylewski, chief of general thoracic surgery at Baptist Health, and Juan Batlle, chief of thoracic imaging at Baptist Health, launched Baptist Health’s lung cancer screening program with the support of Dennis Bookshester.

Screening is available throughout Baptist Health. For eligible patients, Medicare and most private insurance companies cover the screening cost.

The South Florida “Saved by the Scan” comprehensive public awareness campaign includes a video public service announcement, digital and print advertisements, and social media.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login